Transforming growth factor alpha (TGFA) gene is involved in the proliferation and metastasis of various tumors, but its role in cell sensitivity to cisplatin chemotherapy is unclear. In this study, we investigated the mechanism underlying inhibitory effects of cisplatin on growth and proliferation of osteosarcoma cells. Osteosarcoma and normal skeletal muscle tissues were collected from 26 patients by biopsy. TGFA was silenced or overexpressed in Saos-2 osteosarcoma cells by transfection with TGFA-shRNA or TGFA ORF clone, respectively.
INTRODUCTION

Human health and life have been seriously threatened by malignant tumors. The World
Health Organization reported that there were 18.1 million new cancer cases and 9.6 million died in 2018 [1] . In the last few decades, patients with osteosarcomas have been treated by various chemotherapeutic drugs in combination with surgical resection, so their 5-year survival rate has been evidently increased. Due to the development of neoadjuvant chemotherapy and pulmonary metastasis dissection, patients with osteosarcomas are no longer subjected to amputation but limb salvage instead, and their tumor-free survival rate has been elevated to about 60%-70%. However, high-dose chemotherapeutic agents have toxic side effects, accompanied by tumor cell mutation, primary or secondary drug resistance, early pulmonary metastasis and local recurrence [2] . Moreover, it is rather difficult or even impossible to perform surgery for patients with osteosarcomas in the spine, pelvis and other special parts as well as for patients at the advanced stage with recurrence or multiple metastatic foci. These patients can only take high-dose chemotherapeutic drugs, also with unsatisfactory treatment outcomes. Therefore, researchers have endeavored to develop feasible therapies with mild side effects, among which targeted therapy based on molecular biology and genetics has attracted widespread attention.
First prepared in 1844, cisplatin was found to exert strong inhibitory effects on the growth of tumor cells in 1967 [3] . Currently, cisplatin is used in 70%-80% of chemotherapeutic or combined methods for malignant tumors. However, the development and application of platinum drugs are limited because of structural similarity that leads to resistance or crossresistance. Therefore, it is necessary to clarify the mechanism by which cisplatin works, and to augment the sensitivity of osteosarcoma towards chemotherapy by developing targeted drugs.
Peptide growth factors are potent cell growth regulators. By forming a complex biological network, peptide growth factors work as the material basis for intercellular information exchange, and can stimulate cell growth through autocrine, inhibit proliferation through paracrine or promote differentiation and malignant transformation through endocrine [4] .
With a span of 70-100 kb, TGF-α genomic TGFA is located on the human chromosome 2 and has 6 exons. TGFA gene expression is up-regulated in some human tumor cells, being related to their metastasis and invasion. For example, TGFA can regulate the transformation of mammary epithelial cells, and TGFA and EGFR are overexpressed in human breast cancer tissues and various breast cancer cell lines [5] . EGFR antibody or specific kinase inhibitors can block the TGFA/EGFR signaling pathway and prevent breast cancer induced by TGFA overexpression, suggesting that this pathway may play an important role in treatment [6] .
Wang et al. found that TGFA regulated the proliferation and migration of ovarian granulosa cell tumor cells via the KGN signaling pathway, and played a key role in their growth and metastasis [7] . In addition, TGFA participates in the proliferation and metastasis of human osteosarcoma [1, 9] , and plays a dominant role in osteosarcoma growth as an oncogene [9] .
As endogenous, non-coding, highly conserved RNAs, microRNAs (miRNAs) exist in viruses and higher organisms. They participate in many biological processes, including growth, development, cell apoptosis, proliferation and differentiation. In animals, over 50% of miRNA genes in the genome are located in tumor-related or fragile sites [10] .
MiRNAs inhibit or promote tumor growth by regulating the proliferation and metastasis of tumor cells through oncogenes or anti-oncogenes [11] . Members of the miR-376 family are abnormally expressed in many types of tumors. As a member of this family, miR-376c has low expression levels in several kinds of tumor cells, and can inhibit their proliferation and metastasis. Zehavi et al. reported that miR-376c was obviously silenced in melanoma cells, and that overexpression of miR-376b and miR-376c inhibited the expression of insulin-like growth factor 1 receptor and decelerated cell proliferation and metastasis [12] . MiR-376c has low expression in osteosarcoma cells [13] , so it may be involved in cell proliferation and metastasis.
As mentioned above, TGFA gene is related to the proliferation and metastasis of a variety of tumors, but its relationship with the sensitivity to chemotherapy using cisplatin remains elusive. MiR-376c has been predicted to regulate the expression of TGFA, so the sensitivity to chemotherapy using cisplatin may be associated with the miR-376c/TGFA pathway. In this study, we analyzed the relationship of cisplatin with TGFA which played a crucial role in regulating the growth and proliferation of osteosarcoma cell line Saos-2. Afterwards, we studied the association of cisplatin with miR-376c which regulated TGFA in a targeted manner. The findings provide valuable evidence for developing targeted drugs that can enhance the sensitivity of osteosarcoma to chemotherapeutic agents.
MATERIALS AND METHODS
Clinical samples
Fresh osteosarcoma tissues and normal skeletal muscle tissues were collected from patients receiving biopsy in our hospital, immediately placed in liquid nitrogen, and stored at -80°C prior to use. Osteosarcoma was diagnosed by postoperative histopathological examination.
The osteosarcoma tissues were collected from 20 males and 6 females. No patient received radiotherapy or chemotherapy before surgery. The collection process has been approved by the ethics committee of our hospital, and written informed consent has been obtained from all patients.
Cells and reagents
Human osteosarcoma cell line Saos-2 and normal human osteoblasts hFOB were purchased from the Cell Bank of Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences (China). TGFA-shRNA, TGFA ORF clone, miR-376c Sponge and miR-376c mimics plasmids were bought from Wuhan Viraltherapy Technologies Co., Ltd. (China).
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Cisplatin was obtained from Sigma-Aldrich (USA).
The cells were cultured in DMEM (Sigma, USA) containing 10% fetal bovine serum (FBS) (Gibco, USA), 100 U/mL penicillin (Sigma, USA) and 100 U/mL streptomycin (Sigma, USA), and incubated in a 5% CO2 incubator at 37°C with a relative humidity of 95%. The medium was refreshed every 2-3 days until the cells adhered to the wall.
Down-regulation of TGFA expression by transfection
Saos-2 cells infected with empty vector were set as a blank group (Control), those transfected with antisense sequence shRNA were set as a negative control group (Control-shRNA), and those transfected with TGFA siRNA plasmid were set as an experimental group (TGFA-shRNA). Cells in the logarithmic growth phase were digested, counted, seeded in a 6-well plate at a density of 2.5×10 5 /well and placed in a 5% CO2 incubator at 37°C with saturated humidity. When the confluence reached 80%-90%, the cells were transfected with Control-shRNA and TGFA-shRNA plasmids according to the manufacturer's instructions for Lipofectamine ® 2000 reagent (Thermo Fisher Scientific, USA). Specifically, cell-culture medium was replaced with serum-free medium 2 h before transfection. TGFA-shRNA plasmid (4 μg) (4 μg pSliencer TM purchased from Thermo Fisher Scientific (USA) for Control-shRNA, and sterile water with the same volume for Control) was diluted by 0.25 mL of serum-free high-glucose DMEM (Sigma, USA). Meanwhile, 10 μL of Lipofectamine ® 2000 reagent was diluted by 0.75 mL of high-glucose DMEM. The two dilutions were then fully mixed and incubated at room temperature for 20 min. The transfected cells were cultured for 4 h, and then the medium was replaced with complete medium. Saos-2 cells with silenced TGFA gene were finally obtained after G418 screening and passage.
The detailed procedure for G418 screening is shown below. After transfection, cells were cultured for 24 h, passaged in a 1:10 proportion and further cultured. After the cells adhered to the wall, the culture medium was discarded, followed by washing with PBS and addition 7 of fresh G418 screening culture medium. According to the color of culture medium and cell growth state, the medium was refreshed every 3-5 days. In the case of considerable cell death, the concentration of G418 medium was halved to continue screening. After 10-14 days of screening, resistant clones appeared, and drug treatment was stopped to allow the clones to further grow. The cell suspension was then prepared, and the cells were counted and diluted (1/10 μl) by culture medium. Subsequently, culture medium (150 μl/well) and the cell suspension (10 μl/well) were added into 96-well plates sequentially. Then the cells were transferred into 48-well plates and further cultured, from which total RNA was extracted for real-time PCR.
Construction of cells stably overexpressing TGFA
Saos-2 cells infected with empty vector were set as a blank group (Control), those transfected with pcDNA3.1 were set as a negative control group (pcDNA3.1), and those transfected with TGFA ORF clone plasmid were set as an experimental group (TGFA ORF clone). When the confluence reached 80%-90%, the cells were transfected with pcDNA3.1 (Thermo Fisher Scientific, USA) and TGFA ORF clone plasmids according to the manufacturer's instructions for Lipofectamine ® 2000 reagent. Specifically, cell-culture medium was replaced with serumfree medium 2 h before transfection. TGFA ORF clone plasmid (4 μg) (4 μg pcDNA3.1 plasmid, and sterile water with the same volume for Control) was diluted by 0.25 mL of serum-free high-glucose DMEM. Meanwhile, 10 μL of Lipofectamine ® 2000 reagent was diluted by 0.75 mL of high-glucose DMEM. The two dilutions were thereafter completely mixed and incubated at room temperature for 20 min. The transfected cells were cultured for 4 h, and then the medium was replaced with complete medium. Saos-2 cells with overexpressed TGFA gene were finally obtained after G418 screening and passage. Subsequently, the two mixtures were mixed and incubated at room temperature for 20 min.
Down-regulation of miR-376c expression by transfection
The transfected cells were cultured for 4 h and then the medium was replaced with complete medium. Saos-2 cells with down-regulated miR-376c expression were finally obtained after G418 screening and passage.
Construction of cells stably overexpressing miR-376c
Saos-2 cells infected with empty vector were set as a blank group (Control), those transfected with miRNA antisense sequence mimics were set as a negative control group (miR-SCR), and those transfected with miR-376c mimics were set as an experimental group (miR-376c).
When the confluence reached 80%-90%, the cells were transfected with miR-SCR mimics and miR-376c mimics plasmids according to the manufacturer's instructions for Lipofectamine ® 2000 reagent. The transfected cells were cultured for 4 h and then the medium was replaced with complete medium. Saos-2 cells with overexpressed miR-376c were eventually obtained after G418 screening and passage.
Treatment of Saos-2 cells with cisplatin
Saos-2 cells were adjusted to the density of 2.510 5 /mL and treated with different doses of cisplatin (0, 2.5, 5.0, 10.0 mg/L) for 48 h.
Western blot
Saos-2 cells were digested, centrifuged, collected and lysed with RIPA buffer. The total protein concentration was determined according to the instructions of BCA kit (Beyotime Institute of Biotechnology, Shanghai, China). Each sample (50 μg) was subjected to SDS-PAGE, and the product was electronically transferred onto a nitrocellulose membrane that was thereafter blocked with 5% skimmed milk at room temperature for 1 h and incubated with corresponding primary antibody against TGFA (1:1000 diluted) or β-actin (1:1000 diluted) (Abcam, USA) overnight at 4°C. The membrane was then washed and incubated with HRP-labeled anti-mouse secondary antibody (1:5000 diluted) (Abcam, USA) at 37°C for 1 h. Scanning was conducted after ECL development, and the relative protein expression was analyzed by Quantity-One software after internal reference calibration.
Quantitative reverse transcription PCR
When the confluence reached 80%-90%, Saos-2 cells were digested, centrifuged and collected. RNA was then extracted and reverse-transcribed into cDNA according to the instructions of M-MLV kit (Promega, USA). Using cDNA as the template, primers for target genes were used for amplification to detect their expressions in cells. The upstream primer for TGFA was 5'-GCCAACGTCAGTGAGGCAGA-3', and that for miR-376c was 5'-ATAGAGGAAATTCCACGT-3'. The mRNA expressions of TGFA and miR-376c were determined by a TaqMan detection kit. Real-time PCR was carried out using SYBR Green II fluorescent dye and IQ5TM real-time PCR system (Bio-Rad, USA), and the results were analyzed using U6 as the internal reference. The upstream primer for U6 was 5'-CGCAAGGATGACACGCAAATTC-3'. Relative expression was represented as 2 -∆∆Ct . The experiment was performed in triplicate.
MTT assay
After incubation in a six-well plate for 24 h, Saos-2 cells were digested, centrifuged and adjusted to a final density of 1×10 5 /ml in a 96-well plate, with 100 μL per well. The MTT assay was performed on days 1-5, respectively, and the optical density at 490 nm was measured by a microplate reader (PerkinElmer, USA).
BrdU assay
Saos-2 cells were seeded in a Petri dish with a diameter of 35 mm (with a coverslip inside) at 1.5×10 5 /ml, cultured for one day, and synchronized with medium containing 0.4% FBS for three days, leaving most cells in the G0 phase. Before the culture ended, BrdU (Thermo Fisher Scientific, USA; final concentration: 30 μg/L) was added for incubation at 37°C for 40 min. The medium was then discarded, and the coverslip was washed three times with PBS and fixed with methanol/acetic acid for 10 min. Endogenous oxidase was inactivated by 0.3% H2O2-methanol for 30 min after air drying of the fixed coverslip. Subsequently, the coverslip was blocked with 5% normal rabbit serum (Abcam, USA), and nucleic acid was denatured with formamide at 100°C for 5 min. After being cooled on an ice-bath, the coverslip was washed with PBS, and added anti-mouse BrdU monoclonal antibody (Abcam, USA; working concentration: 1:50). Meanwhile, the negative control was added PBS or serum. The ABC method was employed for detection. Hematoxylin and eosin staining was carried out. Total cells and BrdU-positive ones in 10 randomly selected high-magnification visual fields were counted under a light microscope (Olympus, Japan), and the labeling index was calculated.
Luciferase reporter assay
The luciferase activity of sample was detected by E1910 dual luciferase reporter assay system (Promega, USA). The culture medium was discarded 48 h after transfection, and cells were washed twice with PBS. Afterwards, the cells in each well were added 100 μL of passive lysis buffer and gently shaken at room temperature for 15 min to collect the lysate. Afterwards, 20 μL of the lysate was added into GloMax microplate luminometer (Promega, USA). After measurement of the background for 2 s, 100 μL of LARII solution was added into each sample, quickly mixed and measured for 2 s. Subsequently, 100 μL of Stop&Glo reagent was added, rapidly mixed and measured for 2 s.
Statistical analysis
All experiments were repeated three times independently. All data were statistically analyzed by SPSS20.0 software. The categorical data were expressed as mean ± standard deviation (SD). Comparisons between two groups were performed by the independent-sample t test, and those among multiple groups were conducted by one-way analysis of variance with completely random design. In the case of homogeneity of variance, the F test was performed, and the Bonferroni method was used for multiple comparison. In the case of heterogeneity of variance, the Welch approximate F test was conducted, and the Dunnett's T3 method was utilized for multiple comparison. P<0.05 was considered statistically significant.
RESULTS
Correlation between miR-376c and TGFA expressions in osteosarcoma tissues
The relative expression of miR-376c in osteosarcoma tissue was significantly lower than that in normal skeletal muscle tissue (P<0.001), and the expression of TGFA mRNA in osteosarcoma tissue was significantly higher than that in normal tissue (P<0.001). The expressions of miR-376c and TGFA mRNA in osteosarcoma tissues showed a significant negative correlation (P<0.001) (Figure 1 ).
Expressions of miR-376c and TGFA in Saos-2 and hFOB cells
The relative expression of miR-376c in Saos-2 cells was significantly lower than that in hFOB cells (P<0.001), and the relative expression of TGFA mRNA in Saos-2 cells was significantly higher than that in hFOB cells (P<0.001) ( Figure 2 ).
Effects of TGFA on growth and proliferation of Saos-2 cells
Real-time PCR showed that TGFA mRNA expression in the TGFA-shRNA group was down-regulated by 80% compared with that of the Control-shRNA group, indicating that transfection with TGFA-shRNA significantly inhibited the expression (P<0.05). Western blot showed that the expression of TGFA protein in the TGFA-shRNA group was significantly lower than that of the Control-shRNA group (P<0.05) ( Figure 3A) . Therefore, Saos-2 cells with stably silenced TGFA expression had been successfully constructed. As exhibited in Figure 3B , transfection with TGFA-shRNA significantly inhibits the growth of Saos-2 cells (P<0.05). The proliferative capacities of all groups were similar at 24 h, but that of the TGFA-shRNA group significantly decreased at 48 h (P<0.05) ( Figure 3C ). Thus, TGFA promoted the proliferation of Saos-2 cells.
Effects of cisplatin on TGFA protein expression
To evaluate the effects of cisplatin on TGFA, pre-experiment was first carried out, finding that EC50 value was 8 mg/L. Thus, we treated Saos-2 cells with 0, 2.5, 5.0 and 10.0 mg/L cisplatin for 48 h. Real-time PCR and Western blot revealed that both TGFA mRNA and protein expressions decreased with increasing cisplatin concentration (Figure 4 ). Accordingly, cisplatin significantly suppressed TGFA protein expression (P<0.05).
Cisplatin inhibited Saos-2 cell growth by down-regulating TGFA expression
Real-time PCR and Western blot showed that both TGFA mRNA and protein expressions in the TGFA ORF clone group were significantly up-regulated compared with those of the pcDNA3.1 group (P<0.05) ( Figure 5A ). Hence, Saos-2 cells stably overexpressing TGFA had been successfully constructed [9] .
Compared with the pcDNA3.1 group, the growth of the TGFA ORF clone group was significantly facilitated (P<0.05). After treatment with cisplatin (10 mg/L), the growth of the pcDNA3.1 group was significantly suppressed (P<0.05), which was similar to that of the TGFA ORF clone group ( Figure 5B) . The proliferative capacities of all groups were similar at 48 h ( Figure 5C ). Collectively, cisplatin inhibited Saos-2 cell proliferation by down-13 regulating TGFA expression.
Effects of cisplatin on miR-376c expression
With increasing cisplatin concentration, the miR-376c expression level significantly rose after 48 h of treatment (P<0.05) ( Figure 6 ), suggesting that cisplatin promoted the expression.
Cisplatin inhibited Saos-2 cell growth by up-regulating miR-376c expression
MiR-376c expression in the miR-376c Sponge group was down-regulated by approximately 60% compared with that of the Vector group ( Figure 7A ), so transfection with miR-376c
Sponge significantly suppressed the expression (P<0.05). MiR-376c mimics increased miR-376c expression about 47-fold compared with that of the miR-SCR group ( Figure 7B ). Therefore, transfection with miR-376c mimics indeed significantly up-regulated the expression of miR-376c (P<0.05).
The MTT assay exhibited that the growth of Saos-2 cells was suppressed most significantly by combining cisplatin (10 mg/L) treatment with miR-376c transfection (P<0.05) ( Figure   7C ). As displayed in Figure 7D , transfection with miR-376c Sponge facilitates cell growth, further verifying the growth-inhibitory effects of miR-376c. The cell growth was suppressed by cisplatin plus control Vector, which was reversed by combining cisplatin with miR-376c Sponge. Thus, cisplatin suppressed cell growth by up-regulating miR-376c expression.
The proliferative capacities of Saos-2 cells followed a similar trend ( Figure 7E and 7F ), suggesting that cisplatin inhibited cell proliferation by up-regulating miR-376c expression.
Targeted regulatory effects of miR-376c on TGFA
TGFA protein expression of the miR-376c group was significantly down-regulated compared with that of the miR-SCR group (P<0.05) ( Figure 8A) , and the expression of the miR-376c
Sponge group was significantly up-regulated compared with that of the Vector group (P<0.05) ( Figure 8B ). Accordingly, miR-376c effectively inhibited TGFA protein expression, and the expressions of miR-376c and TGFA were negatively associated. The results are in agreement with those of Jin et al. [9] .
There is a 1000 bp 3'UTR region of TGFA near the binding site of wild-type miR-376c.
Meanwhile, the binding site that was predicted by online tools such as TargetScan and miRanda was mutated (i.e. from UCUAUGU to UAUCUAU in the 3'-end sequence). The luciferase activity of wild-type TGFA 3'UTR reporter plasmid was only 70% of that of the control group ( Figure 8C and 8D ), but the activity of the miR-376c Sponge group was 1.3fold that of the control group. In contrast, the luciferase activities of mutant TGFA 3'UTR reporter plasmid in the two transfection groups were similar to that of the control group.
Taken together, miR-376c inhibited TGFA expression by directly interacting with its 3'UTR region. Similar to the results of Jin et al. [9] , miR-376c can suppress TGFA expression in a targeted way.
DISCUSSION
TGFA is highly expressed in digestive tract, gynecological and lung cancers, with the levels recovered to normal after tumor resection [14] . TGFA can synergize with several growth factors and receptors to participate in phenotype transformation, so it has become a target for the diagnosis and treatment of cancers [9] . It has previously been found that TGFA played a critical role in the progression of osteosarcoma [15] .
The expression of a specific gene in mammals can be inhibited by siRNA through direct RNA interference. However, it is still challenging to prepare a specific siRNA for target gene silencing [16] . In this study, silencing TGFA expression suppressed Saos-2 cell growth and DNA synthesis, which was reversed by cisplatin treatment. Therefore, TGFA played a crucial role in Saos-2 cell proliferation. The results provide valuable evidence for augmenting the sensitivity of osteosarcoma to chemotherapeutic agents.
Cisplatin affects tumor cell proliferation and growth depending on the type and origin of cells, as well as the treatment dose and time [17] . Fellenberg et al. found that the growth of liver cancer cells was obviously inhibited with increasing dose of cisplatin. Low-and highdose cisplatin treatments arrested the cells in the G0-G1 phase and the S-G2 phase, respectively [18] . Therefore, cisplatin affects cell proliferation in different ways. In this study, after cisplatin treatment, the growth of Saos-2 cells was significantly suppressed and miR-376c expression increased. Nevertheless, the effects were reversed by transfection with miR-376c Sponge targeting miR-376c. In other words, Saos-2 cells stopped growing due to miR-376c expression, thereby becoming sensitive to chemotherapeutic agent.
Based on the data of the National Cancer Institute, Salter et al. predicted the sensitivities of tumor cells to paclitaxel, 5-fluorouracil, adriamycin and cyclophosphamide by fitting specific mRNA and miRNA profiles [19] . They used 133 breast cancer samples to prove that chemotherapy sensitivity was optimally predicted by combining molecular variables such as estrogen receptor and human epidermal growth factor receptor 2 with corresponding mRNA and miRNA expression profiles.
In animals, miRNA commonly undergoes incomplete base pairing with the 3'UTR region of its target gene [20] . It is rather difficult to identify the binding site of miRNA, which thus requires experimental methods (e.g. RT-PCR, Western blot and luciferase reporter assay) performed based on theoretical prediction of target gene using bioinformatics software. In this study, we conducted the dual luciferase reporter assay [21] to determine whether miR-376c exerted targeted inhibitory effects on TGFA in Saos-2 cells. TGFA has been predicted to be a potential target gene for miR-376c, with a binding site in the 3'UTR region [22] . Accordingly, TGFA expression was down-regulated probably because of up-regulation of miR-376c expression. Meanwhile, it is necessary to clarify the roles of miR-376c in the proliferation, differentiation and apoptosis of osteosarcoma cells, as well as the mechanisms underlying the onset and progression of this cancer. The luciferase activity was inhibited by overexpressing miR-376c whereas enhanced by silencing miR-376c, but neither of the two 16 processes occurred after the binding site of miR-376c was mutated. Hence, miR-376c indeed had a target site for TGFA.
CONCLUSION
In summary, cisplatin inhibited the proliferation of osteosarcoma cells Saos-2 by downregulating TGFA and up-regulating miR-376c. Given that miR-376c exerted targeted inhibitory effects on TGFA expression, cisplatin may suppress the proliferation of osteosarcoma cells via the miR-376c/TGFA pathway.
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